SELLAS Life Sciences Group (RXK3) Price & Analysis

2 Followers

RXK3 Stock Chart & Stats

€9.02

-€0.18(-1.96%)

At close: Jul 30 4:00 PM EDT

€9.02

-€0.18(-1.96%)

Day’s Range― - ―

52-Week Range€1.20 - €14.95

Previous CloseN/A

Volume500.00

Average Volume (3M)570.00

Market Cap

€2.11B

Enterprise Value€2.65B

Total Cash (Recent Filing)€138.44M

Total Debt (Recent Filing)€737.00K

Price to Earnings (P/E)―

Beta0.63

Next Earnings

Nov 18, 2026

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding201,945,710

10 Day Avg. Volume788

30 Day Avg. Volume570

Financial Highlights & Ratios

PEG Ratio0.30

Price to Book (P/B)5.80

Price to Sales (P/S)0.00

P/FCF Ratio-14.48

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€24.47

Price Target Upside171.28% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.18

Revenue Forecast (FY)€31.66M

Bulls Say, Bears Say

Bulls Say

Low LeverageVery low debt materially reduces solvency and interest-burden risk while giving SELLAS greater flexibility to fund clinical development. The repaired equity base also provides a stronger financial foundation than in 2023, despite the company remaining unprofitable.

Oncology PipelineMultiple clinical-stage immunotherapy candidates give SELLAS more than one pathway to create future product value. Targeting tumor-associated antigens across oncology indications can diversify development opportunities, although commercial benefits depend on successful clinical and regulatory progress.

Improved LiquidityThe warrant exercises provide additional capital to support operations and clinical programs over the coming quarters. Greater liquidity can reduce immediate financing pressure and help maintain development continuity, although the associated equity issuance increases the importance of eventual clinical progress.

Bears Say

No Commercial RevenueSELLAS has not established recurring commercial scale because its lead candidates remain in development and revenue has fallen to effectively zero. Persistent operating losses weaken internal funding capacity and leave future financial performance highly dependent on clinical and regulatory success.

Persistent Cash BurnMaterial negative operating and free cash flow means SELLAS is consuming capital rather than generating funds for reinvestment. Continued burn can force additional financing before products generate revenue, creating ongoing funding dependence and potentially reducing the economic share of existing holders.

Dilution And Arbitration SetbackThe arbitration loss adds a direct cash cost and weakens the company’s position around the GPS relationship, while the disclosed financing and incentive actions can increase share dilution. Together, these factors may constrain capital efficiency and reduce the benefit existing holders receive from future progress.

SELLAS Life Sciences Group News

Sellas Life Sciences presents preclinical data on SLS009 at AACR Conference

SELLAS Life Sciences (SLS) Group announced preclinical data from studies evaluating SLS009, its highly selective cyclin-dependent kinases 9...

9d ago

SLS

SELLAS Life Sciences Stock (SLS) Has a Major Catalyst on the Horizon

SELLAS Life Sciences stock was a hot topic among retail traders on Monday as the company is getting...

1M ago

SLS

Moderna data bode well for Sellas into imminent readout, says Maxim

Maxim views Moderna’s (MRNA) melanoma mRNA cancer vaccine results this morning as a “win for cancer vaccines.” Sellas...

2M ago

SLS

MRNA

Sellas Life Sciences price target raised to $35 from $25 at Alliance Global

Alliance Global analyst James Molloy raised the firm’s price target on Sellas Life Sciences (SLS) to $35 from...

2M ago

SLS

Sellas Life Sciences options imply 8.0% move in share price post-earnings

Pre-earnings options volume in Sellas Life Sciences (SLS) is normal with calls leading puts 2:1. Implied volatility suggests...

2M ago

SLS

Moderately bullish activity in Sellas Life Sciences with shares up 7.39%

Moderately bullish activity in Sellas Life Sciences (SLS), with shares up 74c, or 7.39%, near $10.75. Options volume...

2M ago

SLS

Cboe data shows mixed options sentiment in Sellas Life Sciences with shares down 3.3%

Cboe data shows mixed options sentiment in Sellas Life Sciences (SLS), with shares down 34c near $9.95. Options...

2M ago

SLS

Moderately bullish activity in Sellas Life Sciences with shares down 11.17%

Moderately bullish activity in Sellas Life Sciences (SLS), with shares down $1.21 near $9.62. Options volume running well...

2M ago

SLS

SELLAS Life Sciences Faces Adverse Arbitration Ruling

SELLAS Life Sciences Group ( ($SLS) ) has issued an update. On July 24, 2026, a sole arbitrator...

2M ago

SLS

Unusually active option classes on open July 27th

Unusual total active option classes on open include: Leverage Shares 2X Long NBIS Daily ETF (NBIG), Nutrien (NTR),...

2M ago

Sellas Life Sciences rises 11.0%

Sellas Life Sciences (SLS) is up 11.0%, or $1.29 to $13.04. Published first on TheFly – the ultimate...

3M ago

SLS

Sellas Life Sciences rises 10.2%

Sellas Life Sciences (SLS) is up 10.2%, or $1.20 to $12.95. Published first on TheFly – the ultimate...

3M ago

SLS

SELLAS Updates Executive Severance and Change-of-Control Terms

The latest announcement is out from SELLAS Life Sciences Group ( ($SLS) ). On June 24, 2026, SELLAS...

3M ago

SLS

SELLAS Stockholders Approve Governance and Equity Plan Changes

The latest update is out from SELLAS Life Sciences Group ( ($SLS) ). On June 16, 2026, SELLAS...

4M ago

SLS

RXK3 FAQ

What was SELLAS Life Sciences Group’s price range in the past 12 months?

SELLAS Life Sciences Group lowest stock price was €1.20 and its highest was €14.95 in the past 12 months.

What is SELLAS Life Sciences Group’s market cap?

SELLAS Life Sciences Group’s market cap is €2.11B.

When is SELLAS Life Sciences Group’s upcoming earnings report date?

SELLAS Life Sciences Group’s upcoming earnings report date is Nov 18, 2026 which is in 44 days.

How were SELLAS Life Sciences Group’s earnings last quarter?

SELLAS Life Sciences Group released its earnings results on Aug 11, 2026. The company reported -€0.044 earnings per share for the quarter, missing the consensus estimate of -€0.04 by -€0.004.

Is SELLAS Life Sciences Group overvalued?

According to Wall Street analysts SELLAS Life Sciences Group’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does SELLAS Life Sciences Group pay dividends?

SELLAS Life Sciences Group does not currently pay dividends.

What is SELLAS Life Sciences Group’s EPS estimate?

SELLAS Life Sciences Group’s EPS estimate is -0.04.

How many shares outstanding does SELLAS Life Sciences Group have?

SELLAS Life Sciences Group has 201,945,710 shares outstanding.

What happened to SELLAS Life Sciences Group’s price movement after its last earnings report?

SELLAS Life Sciences Group reported an EPS of -€0.044 in its last earnings report, missing expectations of -€0.04. Following the earnings report the stock price went up 7.438%.

Which hedge fund is a major shareholder of SELLAS Life Sciences Group?

Currently, no hedge funds are holding shares in DE:RXK3

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

SELLAS Life Sciences Group Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

350.03%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

SELLAS Life Sciences Group (RXK3) Earnings & Revenues

Historic Earnings Reports

RXK3 Stock 12 Month Forecast

Average Price Target

€24.47

▲(171.28% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","27":"€27","6.75":"€6.75","13.5":"€13.5","20.25":"€20.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26.6937162,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€26.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.46923985,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€24.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.2447635,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€22.24</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6.75,13.5,20.25,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.8,12.022593553846155,13.245187107692308,14.467780661538463,15.690374215384615,16.912967769230768,18.135561323076924,19.358154876923077,20.580748430769233,21.803341984615386,23.02593553846154,24.24852909230769,25.471122646153848,{"y":26.6937162,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.8,11.85147998846154,12.902959976923079,13.954439965384616,15.005919953846155,16.057399942307693,17.10887993076923,18.16035991923077,19.21183990769231,20.263319896153845,21.314799884615386,22.366279873076923,23.417759861538464,{"y":24.46923985,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.8,11.680366423076924,12.560732846153847,13.44109926923077,14.321465692307694,15.201832115384615,16.08219853846154,16.96256496153846,17.842931384615387,18.72329780769231,19.603664230769233,20.484030653846155,21.364397076923076,{"y":22.2447635,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.328,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.652,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.348,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.37,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.115,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.695,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.02,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.779,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.75,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.68,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >